Ting Deng
New trial — T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
New trial
48/100
Opportunity
Commercial fit6/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5
New phase 1 trial NCT06484790 posted by Ting Deng: "T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).
Why nowClinicalTrials.gov record updated 287 days ago.
ConfidenceHigh · 87%